X
[{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 For the Treatment of Melanoma and Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics\u2019 INT230-6 (PORT-1) at November Scientific Conferences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Stimunity","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Provides Update on Clinical-Stage and Development Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"D","amount":"$53.0 million","upfrontCash":"$21.0 million","newsHeadline":"Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Provides Research and Development Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces $6.0 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Portage Biotech
Filters
Companies By Therapeutic Area
Details:
The Company intends to use the net proceeds for clinical development of TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors.
Lead Product(s):
TT-10
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $6.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
September 29, 2023
Details:
Under theagreement, Merck will provide KEYTRUDA for Portage's Phase 1a/1b trial evaluating adenosine 2A receptor antagonist candidate, TT-10 in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Lead Product(s):
TT-10 ,Pembrolizumab
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Merck & Co
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
September 05, 2023
Details:
TT-10 is an orally administered Portage’s adenosine 2A receptor (A2AR) antagonist candidate evaluating in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Lead Product(s):
TT-10
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 26, 2023
Details:
Under the terms of the agreement, Merck will be providing KEYTRUDA for Portage Biotech’s IMPORT-201 trial, a Phase 1/2 study of PORT-2, a liposomal formulation of IMM60, for patients with NSCLC and advanced melanoma (also known as KEYNOTE E69).
Lead Product(s):
IMM60,Pembrolizumab
Therapeutic Area: Oncology
Product Name: IMM60
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Merck & Co
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
November 08, 2022
Details:
TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.
Lead Product(s):
TT-10
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Tarus Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 14, 2022
Details:
As a result of the transaction, Portage acquires four best-in-class assets including TT-10/PORT-6, targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.
Lead Product(s):
PORT-6
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Recipient:
Tarus Therapeutics
Deal Size: $53.0 million
Upfront Cash: $21.0 million
Deal Type: Acquisition
July 06, 2022
Details:
Translational analysis of IMM60 confirms that PORT-2 activates iNKT cells, NK cells and dendritic cells, supporting the mechanism of action to stimulate both the adaptive and innate immune system.
Lead Product(s):
IMM60,Pembrolizumab
Therapeutic Area: Oncology
Product Name: IMM60
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Intensity Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 06, 2022
Details:
Portage, Stimunity and NCI will collaborate with Center for Cancer Research to advance preclinical and clinical development of STING agonists, STI-001 and anti-Receptor for Advanced Glycation End products agents, for possible synergy to enhance the efficacy of cancer vaccines.
Lead Product(s):
STI-001,Undisclosed
Therapeutic Area: Oncology
Product Name: STI-001
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
National Cancer Institute
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
April 25, 2022
Details:
Clinical trials were initiated in 2021 for both of Portage’s lead invariant natural killer T cell (iNKT) agonist programs, PORT-2 (a liposomal formulation iNKT agonist) and PORT-3 (a nanoparticle coformulation of Portage’s iNKT agonist packaged with an antigen).
Lead Product(s):
IMM60,Pembrolizumab
Therapeutic Area: Oncology
Product Name: IMM60
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 31, 2022
Details:
PORT-5 (STI-001), offers a potentially first-in-class approach to developing molecules that activate the STING pathway by packaging a STING agonist in a virus-like particle (VLP), a well-tested delivery system that can be customized and targeted to specific cells.
Lead Product(s):
Virus Like Particles
Therapeutic Area: Oncology
Product Name: PORT-5
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Stimunity
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 09, 2022